Update on the SNG001 drug, an INFbeta therapy for COVID-19 [electronic resource] / an interview with Stephen Holgate.
Material type:
SoundSeries: Henry Stewart talksBiomedical & life sciences collection. Interviews on Covid-19: Publisher: London : Henry Stewart Talks, 2020Description: 1 online resource (1 streaming audio file (13 min.))Other title: Update on the SNG001 drug, an INFβ therapy for COVID-19 | Update on the SNG001 drug, an Interferon-beta therapy for COVID-19Subject(s): Antiviral agents -- Development | Clinical trials | Coronavirus infections -- Chemotherapy | COVID-19 (Disease) -- Prevention | COVID-19 (Disease) -- Treatment | Interferon | Antiviral Agents -- administration & dosage | Clinical Trials, Phase II as Topic | Coronavirus infections -- drug therapy | Coronavirus infections -- prevention & control | COVID-19 -- drug therapy | COVID-19 -- prevention & control | Interferon-beta -- administration & dosage | Interferon-beta -- therapeutic use | Nebulizers and Vaporizers | Pneumonia, Viral -- drug therapy | Pneumonia, Viral -- prevention & control | Precision Medicine | SARS-CoV-2 | Treatment OutcomeOnline resources: Click here to access online | Series Audio interview.
Title from title frames.
Contents: An overview of SNG001 therapy -- Findings of the phase 2 clinical trial -- Treatment potential at different stages of the disease -- Advantages of the treatment delivery mode and accessibility -- Potential use as a prophylaxis treatment -- Follow up clinical trials to be undertaken -- Other treatment settings for INFβ.
Access restricted to subscribers.
Mode of access: World Wide Web.